Related Experiment Video
Updated: Sep 15, 2025
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Development and characterization of a mouse-panda chimeric antibody with neutralizing activity against canine
Zhengguo Wang1, Guishan Ye1, Kuijing He1
1National Key Laboratory of Agricultural Microbiology，Hubei Hongshan Laboratory, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei 430070, China; Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei 430070, China.
Abstract:
Canine distemper (CD) poses as the primary virulent infectious disease threatening the safety of panda populations, and monoclonal antibodies (mAbs) represent a potential therapeutic option for the treatment of CD in pandas. To avoid immune rejection of mouse-derived mAbs in panda clinical treatment, this study utilized a mouse-derived mAb targeting the CDV-H protein to develop a mouse-panda chimeric antibody and established a CHO cell line with stable high-expression of this chimeric antibody. SDS-PAGE results indicated that the chimeric antibody expressed by CHO cells was correctly expressed. Both indirect ELISA and indirect immunofluorescence experiments demonstrated that the chimeric antibody specifically recognized the CDV-H protein and CDV virus. Furthermore, neutralization experiments confirmed its neutralizing effect on CDV. This study successfully prepared the panda-derived chimeric antibody, providing a potential candidate drug reserve for the treatment of CD in pandas.
More Related Videos
07:15Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity
Published on: November 22, 2021
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011